| Name | Title | Contact Details |
|---|
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder (“AUD using our lead investigational new drug product, AD04. A Phase 2b University of Virginia investigator sponsored clinical trial of AD04 for the treatment of AUD showed promising results and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.
Be a part of something bigger. Enhance your eye care practice’s capabilities by partnering with a team that understands your business. Contact us today.
Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The resulting, new therapeutic creates a more targeted molecule with the goal of improving treatment outcomes and improving compliance with treatment regimens. Our initial development areas are in oncology and infectious disease.
Aktiv Pharma Group is a company that develops drug delivery technology for emergency situations, with a focus on the ARAI auto injector for opioid overdose, hypoglycemia, and severe allergies like anaphylaxis.
Family medicine, primary care, and dental service provider for the underserved and uninsured communities of Pinellas County.